

**IN THE CLAIMS**

Applicants have submitted a new complete claim set.

Please amend claim 2 as noted below.

1. (Cancelled)
2. (Currently Amended) A method, comprising:  
    applying, to a tissue surface internally of a mammal, an initially entirely fluent, pre-polymeric material, the pre-polymeric material comprising at least one therapeutic agent, the pre-polymeric material being activatable to a non-fluent, polymeric condition; and  
    polymerizing the pre-polymeric material on the tissue surface by applying heat and/or radiation to form thereon a layer of polymeric, non-fluent material.
3. (Previously Presented) The method of claim 1, wherein the polymerizing step comprises heating the pre-polymeric material.
4. (Previously Presented) The method of claim 1, wherein the polymerizing step comprises cooling the pre-polymeric material.
5. (Previously Presented) The method of claim 1, wherein the polymerizing step comprises mechanically deforming the pre-polymeric material.
6. (Previously Presented) The method of claim 1, wherein the polymerizing step comprises chemically reacting the pre-polymeric material.
7. (Previously Presented) The method of claim 1, wherein the polymerizing step comprises cross-linking the pre-polymeric material.

8. (Previously Presented) The method of claim 1, wherein the polymerizing step comprises applying radiation to the pre-polymeric material.
9. (Previously Presented) The method of claim 1, wherein the polymeric, non-fluent material is biodegradable.
10. (Previously Presented) The method of claim 1, wherein the polymeric material comprises at least one of a carboxylic acid, a polyurethane, a polyester, a polyamide, a polyphosphazine, a polylactone, a polyanhydride, polyethylene, polyvinyl chloride, ethylene vinyl acetate, delta-valerolactone, and p-dioxanone.
11. (Previously Presented) The method of claim 1, wherein the polymeric material comprises polycaprolactone.
12. (Previously Presented) The method of claim 1, wherein the tissue is cardiac tissue.
13. (Previously Presented) The method of claim 1, wherein the tissue is muscle tissue.
14. (Previously Presented) The method of claim 1, wherein the tissue has a hollow geometry.
15. (Previously Presented) The method of claim 1, wherein the tissue is a blood vessel.
16. (Previously Presented) The method of claim 1, wherein the therapeutic agent comprises a growth factor.
17. (Previously Presented) The method of claim 1, wherein the therapeutic agent comprises an anti-thrombotic agent.
18. (Previously Presented) The method of claim 16, wherein the anti-thrombotic agent comprises prostacyclin.

19. (Previously Presented) The method of claim 16, wherein the anti-thrombotic agent comprises a salicylate.
20. (Previously Presented) The method of claim 1, wherein the therapeutic agent comprises a thrombolytic agent.
21. (Previously Presented) The method of claim 19, wherein the thrombolytic agent comprises streptokinase.
22. (Previously Presented) The method of claim 19, wherein the thrombolytic agent is urokinase.
23. (Previously Presented) The method of claim 19, wherein the thrombolytic agent comprises tissue plasminogen activator.
24. (Previously Presented) The method of claim 19, wherein the thrombolytic agent comprises anisoylated plasminogen-streptokinase activator complex.
25. (Previously Presented) The method of claim 1, wherein the therapeutic agent comprises a vasodilating agent.
26. (Previously Presented) The method of claim 24, wherein the vasodilating agent comprises a nitrate.
27. (Previously Presented) The method of claim 24, wherein the vasodilating agent comprises a calcium channel blocker.
28. (Previously Presented) The method of claim 1, wherein the therapeutic agent comprises an anti-proliferative agent.

29. (Previously Presented) The method of claim 27, wherein the anti-proliferative agent comprises colchicine.
30. (Previously Presented) The method of claim 27, wherein the anti-proliferative agent comprises an alkylating agent.
31. (Previously Presented) The method of claim 1, wherein the therapeutic agent comprises an intercalating agent.
32. (Previously Presented) The method of claim 1, wherein the therapeutic agent comprises a growth modulating factor.
33. (Previously Presented) The method of claim 31, wherein the growth modulating factor comprises an interleukin.
34. (Previously Presented) The method of claim 31, wherein the growth modulating factor comprises transformation growth factor beta.
35. (Previously Presented) The method of claim 31, wherein the growth modulating factor comprises a congener of a platelet derived growth factor.
36. (Previously Presented) The method of claim 1, wherein the therapeutic agent comprises a monoclonal antibody.
37. (Previously Presented) The method of claim 1, wherein the therapeutic agent comprises an anti-inflammatory agent.
38. (Previously Presented) The method of claim 36, wherein the anti-inflammatory agent is steroidal.

39. (Previously Presented) The method of claim 36, wherein the anti-inflammatory agent is non-steroidal.
40. (Previously Presented) The method of claim 1, wherein the therapeutic agent is able to modulate vessel tone.
41. (Previously Presented) The method of claim 1, wherein the therapeutic agent is able to modulate arteriosclerosis.
42. (Previously Presented) The method of claim 1, wherein the therapeutic agent is able to modulate the healing response of the tissue surface.